These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 29691722)

  • 1. Applying new Magee equations for predicting the Oncotype Dx recurrence score.
    Sughayer M; Alaaraj R; Alsughayer A
    Breast Cancer; 2018 Sep; 25(5):597-604. PubMed ID: 29691722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score.
    Turner BM; Skinner KA; Tang P; Jackson MC; Soukiazian N; Shayne M; Huston A; Ling M; Hicks DG
    Mod Pathol; 2015 Jul; 28(7):921-31. PubMed ID: 25932962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis.
    Klein ME; Dabbs DJ; Shuai Y; Brufsky AM; Jankowitz R; Puhalla SL; Bhargava R
    Mod Pathol; 2013 May; 26(5):658-64. PubMed ID: 23503643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between modified Magee equation-2 and Oncotype-Dx recurrence scores using both traditional and TAILORx cutoffs and the clinical application of the Magee Decision Algorithm: a single institutional review.
    Glasgow A; Sechrist H; Bomeisl P; Gilmore H; Harbhajanka A
    Breast Cancer; 2021 Mar; 28(2):321-328. PubMed ID: 32951186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer tumor heterogeneity has only little impact on the estimation of the Oncotype DX® recurrence score using Magee Equations and Magee Decision Algorithm™.
    Remoué A; Conan-Charlet V; Deiana L; Tyulyandina A; Marcorelles P; Schick U; Uguen A
    Hum Pathol; 2021 Feb; 108():51-59. PubMed ID: 33245987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does integration of Magee equations into routine clinical practice affect whether oncologists order the Oncotype DX test? A prospective randomized trial.
    Robertson SJ; Ibrahim MFK; Stober C; Hilton J; Kos Z; Mazzarello S; Ramsay T; Fergusson D; Vandermeer L; Mallick R; Arnaout A; Dent SF; Segal R; Sehdev S; Gertler S; Hutton B; Clemons M
    J Eval Clin Pract; 2019 Apr; 25(2):196-204. PubMed ID: 30672056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Magee and Oncotype DX Recurrence Scores in estrogen receptor positive breast cancers.
    Walts AE; Mirocha JM; Bose S
    Breast J; 2018 Nov; 24(6):951-956. PubMed ID: 30230113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using the Modified Magee Equation to Identify Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay (Oncotype DX Assay).
    Hou Y; Tozbikian G; Zynger DL; Li Z
    Am J Clin Pathol; 2017 Jun; 147(6):541-548. PubMed ID: 28449064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Oncotype DX With Modified Magee Equation Recurrence Scores in Low-Grade Invasive Carcinoma of Breast.
    Hou Y; Zynger DL; Li X; Li Z
    Am J Clin Pathol; 2017 Aug; 148(2):167-172. PubMed ID: 28898988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncotype DX
    Rath MG; Uhlmann L; Fiedler M; Heil J; Golatta M; Dinkic C; Hennigs A; Schott S; Ernst V; Koch T; Sohn C; Brucker C; Rom J
    Arch Gynecol Obstet; 2018 Feb; 297(2):443-447. PubMed ID: 29236174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
    Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk stratification of ER-positive breast cancer patients: A multi-institutional validation and outcome study of the Rochester Modified Magee algorithm (RoMMa) and prediction of an Oncotype DX
    Turner BM; Gimenez-Sanders MA; Soukiazian A; Breaux AC; Skinner K; Shayne M; Soukiazian N; Ling M; Hicks DG
    Cancer Med; 2019 Aug; 8(9):4176-4188. PubMed ID: 31199586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset.
    Harowicz MR; Robinson TJ; Dinan MA; Saha A; Marks JR; Marcom PK; Mazurowski MA
    Breast Cancer Res Treat; 2017 Feb; 162(1):1-10. PubMed ID: 28064383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
    Milburn M; Rosman M; Mylander C; Tafra L
    Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer.
    Dodson A; Okonji D; Assersohn L; Rigg A; Sheri A; Turner N; Smith I; Parton M; Dowsett M
    Breast Cancer Res Treat; 2018 Feb; 168(1):249-258. PubMed ID: 29128896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer histopathology is predictive of low-risk Oncotype Dx recurrence score.
    Wilson PC; Chagpar AB; Cicek AF; Bossuyt V; Buza N; Mougalian S; Killelea BK; Patel N; Harigopal M
    Breast J; 2018 Nov; 24(6):976-980. PubMed ID: 30230117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation.
    Biroschak JR; Schwartz GF; Palazzo JP; Toll AD; Brill KL; Jaslow RJ; Lee SY
    Breast J; 2013; 19(3):269-75. PubMed ID: 23614365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncotype DX Breast Cancer recurrence score resists inter-assay reproducibility with RT
    Schildgen V; Warm M; Brockmann M; Schildgen O
    Sci Rep; 2019 Dec; 9(1):20266. PubMed ID: 31889145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection of neoadjuvant treatment based on the 21-GENE test results in luminal breast cancer.
    Morales Murillo S; Gasol Cudos A; Veas Rodriguez J; Canosa Morales C; Melé Olivé J; Vilardell Villellas F; Sanchez Guzman DR; Iglesias Martínez E; Salud Salvia A
    Breast; 2021 Apr; 56():35-41. PubMed ID: 33601299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors influencing Oncotype DX use in the management of early breast cancer: a single centre experience.
    Zhu X; Dent S; Paquet L; Zhang T; Graham N; Song X
    Eur J Cancer; 2014 Oct; 50(15):2544-9. PubMed ID: 25129366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.